Abstract：
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58.9% [95% CI: 54.5-63.1%] vs 35.5% [33.3-37.8%], p < 0.0001). Women had a higher OS rate than men (5-year OS, 34% [95% CI; 31.4-36.7%] vs 27.7% [25.7-29.7%], p < 0.0001). The OS rate was lower in patients aged 40 and older than those under 40, and even lower in those over 65 (5-year OS for ages < 40, 40-64, 65-74, ≥ 75: 74.5% [95% CI; 69.3-79.0%] vs 47.5% [44.4-50.6%] vs 19.3% [16.8-22.0%] vs 7.3% [5.5-9.4%], respectively). This is the first paper to present large-scale data on survival and clinical characteristics in Japanese AML patients.
摘要：
本报告涵盖了多中心的急性髓性白血病（AML）结果，AML的前瞻性观察性研究，骨髓增生异常综合征,和日本的慢性粒单核细胞白血病。从2011年8月至2016年1月，登记了3728名AML患者。其中,42％的人小于65岁，男女比例为1.57：1。中位随访时间为1807天（95%置信区间[CI]：1732-1844天），AML患者(n=3707)的5年总生存率(OS)为31.1%(95%CI:29.5~32.8%).试验入组患者的OS率比未入组患者高1.7倍(5年OS，58.9%[95%CI：54.5-63.1%]vs35.5%[33.3-37.8%]，p<0.0001)。女性的OS率高于男性(5年OS，34%[95%CI；31.4-36.7%]vs27.7%[25.7-29.7%]，p<0.0001)。40岁及以上患者的OS率低于40岁以下患者，65岁以上患者的OS率甚至更低（年龄<40，40-64，65-74，≥75的5年OS：74.5％[95％CI;69.3-79.0％]vs47.5％[44.4-50.6％]vs19.3％[16.8-22.0％]vs7.3％[5.5-9.4％]，分别)。这是第一篇关于日本AML患者生存和临床特征的大规模数据的论文。
